NanoRepro AG (NN6) - Total Liabilities
Based on the latest financial reports, NanoRepro AG (NN6) has total liabilities worth €694.21K EUR (≈ $811.60K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
NanoRepro AG - Total Liabilities Trend (2008–2024)
This chart illustrates how NanoRepro AG's total liabilities have evolved over time, based on quarterly financial data. See NN6 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
NanoRepro AG Competitors by Total Liabilities
The table below lists competitors of NanoRepro AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Quest Resource Holding Corp
NASDAQ:QRHC
|
USA | $109.32 Million |
|
FibroBiologics, Inc. Common Stock
NASDAQ:FBLG
|
USA | $8.62 Million |
|
Blackrock World Mining Trust Plc
LSE:BRWM
|
UK | GBX107.48 Million |
|
Amanet Management & Systems Ltd
TA:AMAN
|
Israel | ILA61.53 Million |
|
KONG SUN (BL25000)
F:KOJ5
|
Germany | €2.32 Billion |
|
HANBIT SOFT Inc
KQ:047080
|
Korea | ₩5.14 Billion |
|
MegaMD Co. Ltd
KQ:133750
|
Korea | ₩16.86 Billion |
|
Pulsenmore Ltd. Ordinary Shares
NASDAQ:PLSM
|
USA | $18.76 Million |
Liability Composition Analysis (2008–2024)
This chart breaks down NanoRepro AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NN6 company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 32.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 23.20 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NanoRepro AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NanoRepro AG (2008–2024)
The table below shows the annual total liabilities of NanoRepro AG from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €884.03K ≈ $1.03 Million |
-18.30% |
| 2023-12-31 | €1.08 Million ≈ $1.27 Million |
-47.01% |
| 2022-12-31 | €2.04 Million ≈ $2.39 Million |
-90.52% |
| 2021-12-31 | €21.54 Million ≈ $25.18 Million |
+577.36% |
| 2020-12-31 | €3.18 Million ≈ $3.72 Million |
+749.78% |
| 2019-12-31 | €374.21K ≈ $437.49K |
+98.93% |
| 2018-12-31 | €188.12K ≈ $219.93K |
-49.61% |
| 2017-12-31 | €373.31K ≈ $436.44K |
-22.03% |
| 2016-12-31 | €478.78K ≈ $559.74K |
+190.84% |
| 2015-12-31 | €164.62K ≈ $192.46K |
-37.88% |
| 2014-12-31 | €265.00K ≈ $309.81K |
+88.29% |
| 2013-12-31 | €140.74K ≈ $164.54K |
-29.07% |
| 2012-12-31 | €198.42K ≈ $231.97K |
+41.75% |
| 2011-12-31 | €139.97K ≈ $163.65K |
-62.53% |
| 2010-12-31 | €373.59K ≈ $436.76K |
+51.56% |
| 2009-12-31 | €246.49K ≈ $288.18K |
+25.89% |
| 2008-12-31 | €195.80K ≈ $228.91K |
-- |
About NanoRepro AG
NanoRepro AG engages in the development, manufacture, and distribution of rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. The company provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. It offers rapid diagnostic tests, such as family planning, and preve… Read more